Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

ClinicalTrials.gov ID: NCT01574326

Public ClinicalTrials.gov record NCT01574326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 2-Week, Randomized, Placebo-Controlled, Fixed Dose Period Followed by a 6-Month, Single-Arm, Open-Label, Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients With Chronic Kidney Disease

Study identification

NCT ID
NCT01574326
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Genzyme, a Sanofi Company
Industry
Enrollment
101 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Sevelamer carbonate Drug

Drug

Eligibility (public fields only)

Age range
Up to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2012
Primary completion
May 31, 2015
Completion
May 31, 2015
Last update posted
Jul 24, 2016

2012 – 2015

United States locations

U.S. sites
23
U.S. states
17
U.S. cities
22
Facility City State ZIP Site status
Investigational Site Number 8003 Birmingham Alabama 35205
Investigational Site Number 8005 Birmingham Alabama 35205
Investigational Site Number 8013 Los Angeles California 90024
Investigational Site Number 8014 San Francisco California 94143
Investigational Site Number 8025 Orlando Florida 32806
Investigational Site Number 8007 Atlanta Georgia 30322
Investigational Site Number 8019 Iowa City Iowa
Investigational Site Number 8012 Baltimore Maryland 21287
Investigational Site Number 8008 Boston Massachusetts 02115
Investigational Site Number 8020 Detroit Michigan 48201
Investigational Site Number 8022 Kansas City Missouri 64108
Investigational Site Number 8023 St Louis Missouri 63110
Investigational Site Number 8017 Livingston New Jersey 07039
Investigational Site Number 8018 Buffalo New York 14222
Investigational Site Number 8009 Greenville North Carolina 27834
Investigational Site Number 8010 Portland Oregon 97201-3098
Investigational Site Number 8011 Philadelphia Pennsylvania 19104
Investigational Site Number 8026 Dallas Texas 75390
Investigational Site Number 8016 Houston Texas 77030
Investigational Site Number 8001 San Antonio Texas 78229
Investigational Site Number 8002 Charlottesville Virginia 22908
Investigational Site Number 8027 Richmond Virginia 23298-0034
Investigational Site Number 8006 Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01574326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 24, 2016 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01574326 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →